Patients who are not currently androgen deprivation therapy at the time of enrollment receive 36 weeks of androgen deprivation therapy comprising goserelin subcutaneously or leuprolide acetate intramuscularly once every 4-12 weeks and oral bicalutamide once daily for 36 weeks. Patients who are already receiving androgen deprivation therapy at the time of enrollment will continue treatment until they have received a total of 36 weeks of therapy.